Study demonstrates strong statistical separation between patients receiving Nexalin's DIFS® technology in combination with escitalopram (Lexapro) vs sham group receiving escitalopram alone Two-thirds of patients receiving the combination therapy showed improvement compared to just one-third of patients receiving medication alone HOUSTON, June 26, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") today announced positive results of a clinical study designed ...